Lilly stock climbs on positive arthritis drug test
A potential rheumatoid arthritis treatment from drugmakers Eli Lilly and Co. and Incyte Corp. fared better than another drug in late-stage testing, Lilly said Tuesday.
A potential rheumatoid arthritis treatment from drugmakers Eli Lilly and Co. and Incyte Corp. fared better than another drug in late-stage testing, Lilly said Tuesday.
The settlement with France-based Sanofi SA clears up uncertainty over a drug that could rack up more than $1 billion in sales by 2020, according to Wall Street analysts.
John Lechleiter, CEO of Eli Lilly and Co., said the company remained confident about its drug pipeline even after it weathered a string of failed clinical trials.
Simon Property Group executive David Contis says technology will enhance, not kill, bricks-and-mortar retail.
Analysts have consistently given the Indianapolis-based company some of the lowest ratings among a group of 16 large drugmakers, but Lilly shares have been on a five-year rally.
Unprecedented results from a cardiovascular study on a diabetes medicine sold by Eli Lilly and Co. turns up the pressure on rival Novo Nordisk, which will release data from a similar study on its competing drug next year.
Eli Lilly shares soared Thursday after study results showed Jardiance sharply reduced chances of dying in diabetic patients at high risk of heart complications. The study prompted at least one analyst to predict the drug could bring in billions of dollars by the end of the decade.
A diabetes pill called Jardiance sold by Eli Lilly and Co. cut deaths from heart attacks and strokes in thousands of patients, the first drug to show promise in helping subdue two of the world’s most rampant health epidemics.
For two years, Eli Lilly and Co. has been building a team of immuno-oncology researchers in New York City and has struck a series of deals with other drug companies.
A new analysis shows attempts by drugmakers to raise prices are being wiped out in negotiations with managers of drug insurance benefits like Express Scripts Holding Co. and CVS Health Corp.
The experimental medicine, called romosozumab, showed better results than Eli Lilly and Co.’s Forteo after 12 months, Amgen and UCB said in a joint statement Wednesday.
Eli Lilly and Co. won a court ruling that will keep generic versions of the chemotherapy drug Alimta off the U.S. market until a patent expires in 2022.
Lilly’s stock had its biggest intraday gain since 2009 Thursday after it announced trial results that showed Jardiance lowered the risk of heart attacks, stroke and death in a large trial of adults with type 2 diabetes.
A jury found Lilly isn't liable for withdrawal symptoms experienced by a woman who quit the antidepressant Cymbalta. The verdict may give the drugmaker leverage in fending off more than 5,000 other lawsuits over the drug.
The drugmaker faces as many as 5,000 cases claiming it downplayed Cymbalta’s withdrawal risks, which allegedly include electrical-shock sensations, vomiting and insomnia.
Anthem’s $54 billion bid for rival insurer Cigna is twice the size of the next-largest acquisition in the Indianapolis area, which occurred nearly a decade ago.
Eli Lilly and Co.’s profits plunged 18 percent in the second-quarter but still easily beat the lowered expectations of Wall Street analysts.
Shares of Eli Lilly and Co. stagnated in Wednesday morning trading as investors and patients wished that the effects of solanezumab were more pronounced. Rival Biogen offered muddy results from its own Alzheimer’s drug.
New data released Wednesday morning suggest that Eli Lilly and Co.’s Alzheimer’s drug has a modest but lasting impact on the memory-sapping disease. But analysts worry the impact is too small to be meaningful.
Immunocore Ltd., which this week achieved the biggest private fundraising by a European biotechnology firm in 10 years, plans to accelerate development of its cancer therapy using the money and seek expedited approval.